PMID- 28621081
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20181202
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 46
IP  - 2
DP  - 2017 Jul
TI  - Letter: anti-TNF dose de-escalation in Crohn's disease-a case-by-case decision.
PG  - 212
LID - 10.1111/apt.14128 [doi]
FAU - Imperatore, N
AU  - Imperatore N
AUID- ORCID: 0000-0003-3230-6832
AD  - Gastroenterology, Department of Clinical Medicine and Surgery, School of Medicine
      "Federico II" of Naples, Naples, Italy.
FAU - Testa, A
AU  - Testa A
AD  - Gastroenterology, Department of Clinical Medicine and Surgery, School of Medicine
      "Federico II" of Naples, Naples, Italy.
FAU - Caporaso, N
AU  - Caporaso N
AD  - Gastroenterology, Department of Clinical Medicine and Surgery, School of Medicine
      "Federico II" of Naples, Naples, Italy.
FAU - Rispo, A
AU  - Rispo A
AD  - Gastroenterology, Department of Clinical Medicine and Surgery, School of Medicine
      "Federico II" of Naples, Naples, Italy.
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
CON - Aliment Pharmacol Ther. 2017 Apr;45(7):923-932. PMID: 28164321
MH  - Adalimumab
MH  - Antibodies, Monoclonal
MH  - *Crohn Disease
MH  - Humans
MH  - Infliximab
MH  - *Tumor Necrosis Factor-alpha
EDAT- 2017/06/18 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/06/17 06:00
PHST- 2017/06/17 06:00 [entrez]
PHST- 2017/06/18 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
AID - 10.1111/apt.14128 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2017 Jul;46(2):212. doi: 10.1111/apt.14128.